You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum

Article info

Article menu

Download PDFPDF

IGCS meeting abstracts
Plenary sessions
Plenary 1
IGCS19-0523
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
Free

Authors

Citation

Grisham R, Monk J B, Banerjee S, et al
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
International Journal of Gynecologic Cancer 2019;29:A1.

Publication history

  • First published September 18, 2019.
Online issue publication 
September 18, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.